News Releases

May 24, 2022
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
May 12, 2022
Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022
Synlogic Announces First Quarter 2022 Conference Call and Webcast
April 28, 2022
Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium
April 26, 2022
Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
April 1, 2022
Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
March 17, 2022
Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 10, 2022
Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
March 3, 2022
Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
February 24, 2022
Synlogic To Present at Upcoming Investor and Industry Conferences
February 8, 2022
Synlogic To Present at Upcoming Investor and Industry Conferences
January 6, 2022
Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences
Displaying 49 - 60 of 222